COMPARISON
Glucagon vs Liraglutide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Glucagon is authorised or registered in 10 and Liraglutide in 10 of the 10 registers read. Glucagon: highest phase Phase 4 (after approval). Liraglutide: highest phase Phase 4 (after approval). 450 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Glucagon | Liraglutide | |
|---|---|---|
| Registered trials differs | 1514 clinicaltrials.gov · 2026-10-03 | 518 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Liraglutide openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-12-16 ema · 2026-10-03 | 2009-06-30 ema · 2026-10-03 |
| ATC code differs | H04AA01 ema · 2026-10-03 | A10BJ02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Glucagon | placebo | Liraglutide | placebo |
|---|---|---|---|---|
| Nausea | - | - | 26.4% | 7.4% |
| Diarrhoea | - | - | 13.1% | 6.1% |
| Nasopharyngitis | - | - | 12.4% | 9.3% |
| Vomiting | - | - | 9.0% | 2.1% |
| Constipation | - | - | 8.8% | 3.1% |
| Hypoglycaemia | - | - | 8.7% | 3.3% |
| Headache | - | - | 8.3% | 5.9% |
| Decreased appetite | - | - | 6.6% | 1.2% |
| Upper respiratory tract infection | - | - | 6.0% | 4.7% |
| Dyspepsia | - | - | 5.3% | 1.3% |
Trial register Glucagon: 2 placebo-controlled trials; Liraglutide: 42. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Glucagon side effects · Liraglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Glucagon | Liraglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
450 registered trials include both
| NCT06836284 | The Evira Study: Additional Support During Obesity Treatment RECRUITING · updated 2026-09-10 |
|---|---|
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry NOT_YET_RECRUITING · updated 2026-08-26 |
| NCT05965908 | Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome COMPLETED · updated 2026-08-25 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
| NCT03883412 | Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) RECRUITING · updated 2026-08-12 |
| NCT05313529 | LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes COMPLETED · updated 2026-08-06 |
| NCT06374875 | Fibrosis Lessens After Metabolic Surgery RECRUITING · updated 2026-07-31 |
| NCT07225829 | A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis ACTIVE_NOT_RECRUITING · updated 2026-07-27 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07225816 | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide RECRUITING · updated 2026-07-21 |
| NCT04775082 | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity ACTIVE_NOT_RECRUITING · updated 2026-07-09 |
| NCT07677865 | GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation COMPLETED · updated 2026-07-01 |
| NCT07640139 | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes ENROLLING_BY_INVITATION · updated 2026-06-10 |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients Wit RECRUITING · updated 2026-06-08 |
| NCT07590219 | Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity ACTIVE_NOT_RECRUITING · updated 2026-05-15 |
| NCT04575844 | Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome RECRUITING · updated 2026-05-06 |
| NCT02944500 | Saxenda: Underlying Mechanisms and Clinical Outcomes ACTIVE_NOT_RECRUITING · updated 2026-05-01 |
| NCT03856632 | Liraglutide Effect in Atrial Fibrillation ACTIVE_NOT_RECRUITING · updated 2026-05-01 |
| NCT07539584 | Adiponectin in Patients With Metabolic Disorders COMPLETED · updated 2026-04-22 |
| NCT06903923 | Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy RECRUITING · updated 2026-04-17 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.